PFIZER INC. $24 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 7.5 billion; Market cap: $180.0 billion; Price-to-sales ratio: 2.8; Dividend yield: 3.7%; TSINetwork Rating: Above Average; www.pfizer.com) plans to spin off its animal health subsidiary, which makes drugs for livestock and pets, as a separate, publicly traded company. As part of this plan, Pfizer will sell up to 20% of this business. The new company, which will be called Zoetis Inc., supplied 6% of Pfizer’s 2011 revenue of $67.4 billion.
Pfizer should complete the offering in the first half of 2013. After that, it will probably hand out its remaining shares in Zoetis to its own shareholders.
Pfizer is a buy.